Hari Kiran Chereddi
CEO
Pharma, Entrepreneur
Hyderabad, India
Listen to Hari’s Podcast!
Hari Kiran Chereddi is the Managing Director of HRV Global Life Sciences & CEO at New Horizon Global Pharma.
Hari was listed in the Forbes Global CEO list in 2010/2011 & 2012. Hari has served and continues to serve on a number of prestigious international entities including the prestigious Columbia Law School Task Force which helps promote US-India Clean Energy investments, CII (Confederation of Indian Industries), Bureau of Indian Standards, Bureau of Energy Efficiency, Hyderabad Angels and many more.
After being in a senior leadership role for Bank of America as Head of Business Operations, Hari Kiran Chereddi quit a successful corporate life to set up Sujana Energy (a group company of the USD 2.5 Bn Industrial conglomerate, Sujana Group). He helped device a new spectrum in the Solar energy sector which was industry defining at that time and led Sujana Energy to emerge as one of India’s Top 10 player in the clean energy space.
Not one to be happy in his comfort zone, after Solar energy, it was Pharmaceuticals. Most recently, he served as executive director at Sriam Labs (now a group company of the Pharma major, Laurus Labs). During this period, he transitioned a family run enterprise into a professionalized organization with operational excellence and execution capabilities, creating an exit event by merging Sriam Labs into Laurus Labs. Laurus Labs is now listed on the Indian Stock Markets and part of the index.
In the last 6 years, Hari has built two large scale market expansion & manufacturing companies called HRV Global Life Sciences & New Horizon Global Pharma; both of which are India’s first virtual API companies. Both companies have an active presence, teams & offices in India, USA, Switzerland, Lithuania, Dubai & Turkey; with revenues in excess of USD 75 Mn..
For someone who draws inspiration from creative business models, today the company is the first-of-its-kind which is helping companies access relatively opaque pharmaceutical markets across the world & enjoy a leadership position in this area. Hari leads the pack in creating value through market expansion, orphan drug manufacturing, technology transfers and assured supply contracts through his deep client centric relationships. Notably, the companies have recently filed 3 US Drug Master Files and have 14 other new drugs in pipeline.
Hari is also an active angel investor & mentor. In the last 3 years, he has successfully exited over 6 investments with an average RoCE of 6.5x while holding investments in 4 other ‘promising’ companies. In addition to being a consummate senior executive, he has authored over 30 professional articles, and delivered over 50+ speeches at various professional forums around the world. His career represents success in the corporate world, innovative entrepreneurship and best of breed academics.
Hari is a Computer Science Engineer from India & an MBA in Supply Chain Management and Finance from USA. Keeping his keen academic interest active, Hari Kiran Chereddi is currently pursuing his Doctorate (PhD) with research focus on ‘Usable Best practices & models for seamless Inventory Management in the Pharmaceutical Industry’. He is also pursuing his OPM (Owner President Management) Program at Harvard Business School.
Hari is an avid sportsman, who as a professional badminton player, represented India in over 25 International tournaments in the men’s doubles circuit till December 2019. His career best BWF World Tour Ranking of #56.
Hari is a cooking enthusiast, a beer lover and a travel aficionado who treasures his most cherished moments with family and friends.
Hari is married to Suma, a successful entrepreneur herself, who runs 5 restaurants in India. The couple have 2 kids, a 16-year-old girl (Yashita) & a 13-year-old boy (Vihaan). Hari is also an active member of Young Presidents Organization (YPO) and serves in various leadership positions within.
More details on his LinkedIn Page.
Hari Kiran Chereddi is also featured on our premiere Features Page, and you can read his podcast interview transcript.
